Fig. 6.
Growth rates and predicted growth rates of KRASWT PDXs treated with either Selinexor or a tyrosine kinase inhibitor. Mice were treated with erlotinib (50mg/kg) 5x/week or crizotinib (50mg/kg) 5x/week. PHLC137: n = 4/arm; PHLC148: n = 4/arm. (A) Growth patterns over time. Faded lines in the background are the measured tumor growth patterns of individual mice and dark lines represent predicted growth curves generated from log linear mixed effects modeling [39]. (B) Predicted change in weekly growth rates for treatment compared to vehicle, where vehicle was normalized to equal a weekly growth rate of 1.00. (C) Raw predicted weekly growth rates. Values > 1.00 represent tumor growth; values < 1.00 represent tumor shrinkage. Plots are presented with confidence intervals and FDR adjusted p-values: * = p < 0.05; ** = p < 0.01; *** = p < 0.005; ****= p < 0.001.